Lifetree Clinical Research Expands Research Bed Capacity
Lifetree Clinical Research
has expanded its in-patient capacity from 60 to 75 beds in the early stage research unit at the 35,000-square-foot facility located at 700 E. 3838 S. in Salt Lake City, Utah. This expansion represents a greater than 100 percent increase in size since Lifetree Clinical Research was founded in 2003 at the same address as a 5,000-square-foot facility with eight beds.
The 25 percent increase in beds will allow Lifetree to conduct larger Phase I clinical research studies and support expansion into early stage research in new therapeutic areas such as experimental human models, Alzheimer’s disease, Hepatitis C, and broadened Neuropsychiatric capabilities. Despite an uncertain climate facing many of the nation’s contract research organizations, many of which reduced or eliminated bed capacity over the last four years, Lifetree continues to experience record growth and an expanding client base representing many of the nation’s leading pharmaceutical and biotech research and development companies.
Lifetree currently employs more than 100 Salt Lake City area residents in addition to other supporting personnel throughout the United States.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
